ContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies August 3, 2017
ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017 June 1, 2017
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia May 25, 2017
ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) April 19, 2017
ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update March 15, 2017
